The final experimental results showed that TOP2A plays an important role in the malignant transformation of lung cancer through the upregulation of Wnt3a and immune checkpoint (PD-L1), suggesting the potential therapeutic value of targeting Wnt3a in inhibiting the progression and angiogenesis of non-small cell lung cancer. This evidence concerns the gene TOP2A and non-small cell lung carcinoma.